BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to …
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals Read More »










